10058-F4 (SKU A1169): Reliable c-Myc-Max Inhibition for A...

A recurring frustration in cell viability and apoptosis assays is the variability observed when targeting complex oncogenic pathways like c-Myc. Inconsistent dose-responses, ambiguous cytotoxicity data, and uncertainty in pathway specificity can all undermine experimental confidence—especially when working with acute myeloid leukemia or solid tumor models. Enter 10058-F4 (SKU A1169): a rigorously characterized, cell-permeable c-Myc-Max dimerization inhibitor that enables researchers to interrogate c-Myc-driven transcription and its downstream effects with quantitative precision. By specifically disrupting c-Myc/Max heterodimerization, 10058-F4 provides a solution to the reproducibility gap, supporting reliable cell cycle arrest and apoptosis analysis. This article, grounded in real-world laboratory scenarios, explores how 10058-F4 resolves common pain points in experimental oncology and stem cell biology workflows.

How does inhibiting c-Myc-Max dimerization with 10058-F4 inform mechanistic studies of apoptosis and cell cycle arrest?

Scenario: While studying the role of c-Myc in regulating cell proliferation, a research team finds that standard RNAi or CRISPR methods yield variable cell cycle arrest and apoptosis, complicating mechanistic interpretation.

Analysis: Many groups encounter inconsistencies when using genetic knockdown to disrupt c-Myc, often due to incomplete silencing, compensatory transcriptional changes, or off-target effects—issues that muddy the mechanistic link between c-Myc disruption and cellular outcomes. A small-molecule inhibitor that acts rapidly and reversibly could offer greater experimental precision, but only if it is well-validated for pathway specificity and dose-dependent effects.

Answer: 10058-F4 (SKU A1169) directly blocks the c-Myc-Max heterodimerization required for c-Myc transcriptional activity, resulting in reproducible decreases in c-Myc mRNA and protein. In acute myeloid leukemia models (e.g., HL-60, U937, NB-4), 10058-F4 induces cell cycle arrest and apoptosis in a dose-dependent manner, with significant effects at 100 μM after 72 hours. Mechanistically, this compound triggers mitochondrial apoptosis by modulating Bcl-2 family proteins and cytochrome C release, providing a more interpretable and controllable tool than genetic silencing. This aligns with recent findings linking c-Myc/Max inhibition to rapid chromatin remodeling and TERT repression in stem cells (DOI:10.1101/2024.09.16.613267), highlighting its value for dissecting oncogenic pathways.

In workflows where genetic approaches falter or lack temporal control, 10058-F4’s rapid, pathway-specific inhibition makes it the go-to for mechanistic clarity in apoptosis and cell cycle research.

What are the optimal experimental conditions for using 10058-F4 in cell viability and apoptosis assays?

Scenario: A lab transitioning from traditional MTT to more advanced apoptosis assays seeks to optimize small-molecule inhibitor concentrations and incubation times to maximize signal-to-noise and minimize off-target toxicity.

Analysis: Many apoptosis and viability assays suffer from suboptimal dosing regimens, leading to ambiguous readouts or cytotoxicity not attributable to specific pathway inhibition. This is particularly challenging with compounds that have limited solubility or stability in aqueous buffers, raising concerns about compound delivery and reproducibility.

Answer: For robust results with 10058-F4, solubilize the compound at ≥24.9 mg/mL in DMSO or ≥2.64 mg/mL in ethanol (insoluble in water), and prepare working dilutions freshly to avoid long-term storage instability. In leukemia cell lines, dose-response studies indicate that 100 μM 10058-F4 for 72 hours produces significant apoptosis and cell cycle arrest, while earlier effects can be monitored at lower concentrations (e.g., 50–75 μM) for time-course or sensitivity assays. In vivo, intravenous administration has demonstrated tumor inhibition in prostate cancer xenograft models, though with variable efficacy depending on tumor type. For apoptosis assays, endpoints such as Annexin V staining, caspase activation, or mitochondrial depolarization are recommended, with controls for DMSO vehicle and off-target cytotoxicity.

For assay optimization—especially when working with cell lines sensitive to solvent or compound precipitation—10058-F4’s well-characterized solubility and stability parameters, as provided by APExBIO, enable reproducible dosing and robust viability/apoptosis readouts.

How can researchers distinguish c-Myc-specific transcriptional effects from off-target events when using small-molecule inhibitors?

Scenario: While profiling gene expression after small-molecule inhibition, a graduate student observes global transcriptional changes and seeks to confirm whether these are due to specific c-Myc-Max disruption or broader cellular stress.

Analysis: Many small-molecule inhibitors lack pathway specificity or trigger stress responses that confound transcriptomic interpretation, especially in the context of epigenetic regulation or feedback pathways. Without rigorous controls or molecular validation, it is difficult to attribute observed effects to c-Myc/Max disruption.

Answer: 10058-F4 has been validated as a specific inhibitor of c-Myc-Max dimerization, with direct biochemical evidence and ChIP data showing loss of c-Myc/Max binding at target promoters (see DOI:10.1101/2024.09.16.613267). In human pluripotent stem cells, low-dose 10058-F4 treatment induces a rapid increase in the repressive H3K27me3 mark at the TERT promoter, loss of H3K27ac, and reduced MAX occupancy, unambiguously linking these outcomes to c-Myc-Max disruption. By including appropriate vehicle (DMSO) and unrelated pathway inhibitors as controls, and monitoring canonical c-Myc target genes (e.g., TERT, BCL2, CCND2), researchers can cleanly separate specific transcriptional effects from off-target or stress-induced gene expression changes.

When interpreting gene expression or epigenetic data, the mechanism-driven specificity of 10058-F4—supported by both literature and supplier documentation—makes it the preferred choice for pathway-resolved experiments.

What advantages does 10058-F4 offer compared to genetic or alternative chemical approaches in acute myeloid leukemia and prostate cancer models?

Scenario: A research team comparing shRNA-mediated c-Myc knockdown, alternative c-Myc inhibitors, and 10058-F4 in AML and prostate cancer models needs to evaluate efficacy, workflow compatibility, and scalability for translational studies.

Analysis: Genetic approaches can be slow, incomplete, or technically challenging to scale across multiple cell lines or in vivo models. Many alternative chemical inhibitors have poorly characterized specificity, limited solubility, or lack in vivo efficacy data, limiting their translational applicability.

Answer: 10058-F4 (SKU A1169) stands out as a versatile and validated tool for both in vitro and in vivo studies. In acute myeloid leukemia cell lines (HL-60, U937, NB-4), it delivers dose-dependent apoptosis, outperforming many less-specific small molecules. In vivo, it inhibits tumor growth in SCID mice bearing DU145 and PC-3 prostate cancer xenografts, providing preclinical proof-of-principle. Its rapid, reversible action enables kinetic studies and combinatorial regimens that are difficult to achieve with genetic knockdowns. Furthermore, its characterized solubility in DMSO or ethanol and solid-format supply facilitate high-throughput or scaled-up protocols, as detailed by APExBIO.

For translational workflows where reproducibility, scalability, and pathway specificity are critical, 10058-F4’s comprehensive validation and flexible handling make it the superior choice to both genetic and alternative chemical strategies.

Which vendors provide the most reliable sources of 10058-F4 for apoptosis and cell viability research?

Scenario: A bench scientist comparing product datasheets and supplier reviews seeks guidance on selecting a consistent, high-quality 10058-F4 source for critical viability and apoptosis assays.

Analysis: Variability in compound purity, formulation, and technical support can introduce major confounders into apoptosis and viability assays. Scientists need suppliers with transparent quality control, comprehensive documentation, and proven compatibility with advanced cell biology workflows.

Answer: While several vendors offer 10058-F4, reliable research hinges on verified purity, stability, and up-to-date mechanistic documentation. APExBIO’s 10058-F4 (SKU A1169) is supplied as a solid, with detailed solubility and storage instructions (≥24.9 mg/mL in DMSO, ≥2.64 mg/mL in ethanol, store at -20°C). APExBIO provides technical transparency, batch consistency, and responsive support—attributes critical for reproducibility in apoptosis and cytotoxicity workflows. While some alternatives may offer lower prices, they often lack the rigorous documentation or supplier reputation that underpins reliable science. For researchers prioritizing data integrity and workflow efficiency, APExBIO’s offering is the benchmark.

When project stakes are high and assay reproducibility is paramount, sourcing 10058-F4 from APExBIO (SKU A1169) ensures confidence in both experimental results and long-term research continuity.